Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Jazz Pharmaceuticals plc reports developments across a global biopharma portfolio focused on rare diseases, including epilepsies, cancers and sleep disorders. Recurring updates cover commercial performance for Xywav, Epidiolex and oncology products, plus medical-conference data and real-world evidence for neuroscience and oncology programs.
Company news also includes regulatory and clinical progress for Ziihera (zanidatamab-hrii) in HER2-expressing tumors, including gastroesophageal adenocarcinoma and biliary tract cancer, along with research involving Zepzelca, Modeyso and other pipeline candidates. Updates frequently address financial results, guidance, investor conferences, collaborations and portfolio strategy.
Jazz Pharmaceuticals announced positive top-line results from a Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with atezolizumab for first-line maintenance treatment of extensive-stage small cell lung cancer (ES-SCLC). The combination demonstrated statistically significant improvement in overall survival and progression-free survival compared to atezolizumab alone.
Key points:
- Jazz plans to submit a supplemental New Drug Application in the first half of 2025
- The combination was generally well-tolerated with no new safety signals
- Approximately 30,000 new cases of SCLC are reported annually in the U.S., with a majority diagnosed at extensive stage
- Zepzelca is currently the most widely used agent in second-line SCLC treatment in the United States
Jazz Pharmaceuticals' 2023 Corporate Sustainability and Social Impact Report highlights the company's commitment to employee well-being. The report outlines initiatives in financial, physical, mental, and emotional health. Key offerings include:
1. Competitive compensation with bonus plans and equity incentives
2. A global Employee Stock Purchase Plan
3. Comprehensive health benefits, including 25 therapy/coaching sessions annually
4. A Wellbeing Reimbursement Account, utilized by over 81% of eligible employees
5. Flexible work arrangements through 'Jazz Remix'
The company reports a decline in voluntary attrition from 13% to 7% and an 11% increase in job applications. A July 2023 survey showed high employee satisfaction with the Jazz Remix model, with 79% reporting improved overall satisfaction working at Jazz.
Jazz Pharmaceuticals emphasizes the importance of its team members in driving the company's success. The company is committed to developing meaningful products for serious unmet medical needs while fostering a high-performance culture based on shared values and purpose. Jazz prides itself on being a great workplace that embraces flexibility, diversity, and mutual respect.
The company's culture is characterized by vibrant enthusiasm, recognizing that both art and science benefit from improvisation and collaboration within a structured environment. Jazz believes that when exceptional talents come together in such a setting, the possibilities are limitless. The press release encourages interested individuals to learn more about career opportunities at Jazz Pharmaceuticals.
Jazz Pharmaceuticals, a purpose-led, people-centric company, emphasizes employee engagement and cultivating a unique culture. The company's approach includes:
1. Continuous listening through surveys, focus groups, and town halls, with 2023 Pulse surveys showing 85% of employees feel connected to the company's purpose and 81% recommend Jazz as a good place to work.
2. Diversity, Equity, Inclusion, and Belonging (DEIB) initiatives to create a workplace where everyone can be their authentic selves.
3. Employee Resource Teams (ConcERTos) and Affinity Forums to foster inclusivity and provide spaces for underrepresented groups and allies.
These efforts aim to create a welcoming environment, drive better business outcomes, and enable employees to do their best work in transforming patients' lives.
Jazz Pharmaceuticals presented updated Phase 2 data for zanidatamab, a dual HER2-targeted bispecific antibody, in combination with chemotherapy for HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA) at ESMO 2024. Key findings include:
- Confirmed objective response rate (cORR) of 84%
- Median duration of response of 18.7 months
- Median progression-free survival (mPFS) of 15.2 months
- Kaplan-Meier–estimated 30-month overall survival of 59%
The safety profile remained manageable with no new safety signals. Jazz continues to enroll patients in the Phase 3 HERIZON-GEA-01 trial, with top-line data expected in Q2 2025.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024 from September 13-17 in Barcelona, Spain. Key highlights include:
1. New and updated data from a Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy for first-line treatment of HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA).
2. Data from a Phase 2 study of zanidatamab combined with chemotherapy and bevacizumab as first-line treatment in HER2-positive metastatic colorectal cancer.
3. Findings from a Phase 2 trial evaluating Zepzelca® (lurbinectedin) and irinotecan in relapsed small cell lung cancer (SCLC) patients.
The company expects results from a Phase 3 clinical trial of zanidatamab in GEA in Q2 2025, potentially supporting global regulatory submissions.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will present eight abstracts at the 15th European Epilepsy Congress (EEC) in Rome, Italy, from September 7-11, 2024. The presentations focus on Epidiolex/Epidyolex (cannabidiol) and its effects on patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS).
Key highlights include:
- BECOME Caregiver Survey results showing improvements in seizure frequency (87%), severity (81%), and non-seizure outcomes in patients using Epidyolex with clobazam
- Post-hoc analysis of GWPCARE3 and GWPCARE4 trials demonstrating clinically meaningful reductions in drop seizures for LGS patients
- Real-world data suggesting high rates of initial misdiagnosis in LGS and DS patients
- Analysis of ketogenic diet effects on cannabidiol plasma concentration and seizure reduction
The presentations aim to build scientific evidence supporting Epidyolex's holistic impact on patients, families, and caregivers.
Jazz Pharmaceuticals announced the pricing of $850 million in 3.125% exchangeable senior notes due 2030, with an option for an additional $150 million. The notes, issued by Jazz Investments I , will mature on September 15, 2030, with a 3.125% annual interest rate. The initial exchange rate is 6.5339 ordinary shares per $1,000 principal amount, equivalent to $153.05 per share. Jazz expects $833.7 million in net proceeds, planning to use $350 million to prepay term loans. Concurrently, Jazz repurchased $150 million of its ordinary shares at $109.32 per share.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced that its subsidiary, Jazz Investments I , plans to offer $850 million in exchangeable senior notes due 2030 to qualified institutional buyers. The notes will be exchangeable under certain conditions, with the option to settle in cash, ordinary shares, or a combination. Jazz intends to use the proceeds to prepay up to $350 million of term loans and for general corporate purposes. Additionally, Jazz expects to repurchase up to $150 million of its ordinary shares concurrently with the offering. The notes will be unsecured obligations, guaranteed by Jazz Pharmaceuticals, and will rank pari passu with existing 2026 notes but subordinate to secured debts.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced top-line results from a Phase 3 trial in Japan evaluating cannabidiol oral solution (Epidiolex/Epidyolex) for treating seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. The trial did not meet its primary efficacy endpoint of reducing seizure frequency compared to baseline in Japanese pediatric patients. However, numeric improvements were observed in primary and secondary endpoints, and no new safety signals were identified.
Despite not meeting the primary endpoint, Jazz remains confident in Epidyolex's clinical profile, citing its success in five previous Phase 3 trials involving over 900 patients globally. The company plans to continue collecting data and engage with Japanese regulatory authorities regarding a potential new drug application.